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Abstract  
 
A landmark resolution on cancer prevention and control was adopted by Member 
States at the World Health Assembly 2017, noting that “risk reduction has the 
potential to prevent around half of all cancers” and urging “to promote cancer 
research to improve the evidence base for cancer prevention and control”. Public 
health oriented strategies for cancer prevention and their optimal application in 
effective real-life programmes will be vital to circumvent the dramatic health and 
economic implications of a strategy and healthcare expenditure based primarily on 
cancer treatment. The inter-disciplinary nature of cancer prevention stretches from the 
sub-microscopic study of cancer pathways through to the supra-macroscopic analysis 
of the “causes of the causes”, encompassing socio-economic and environmental 
factors. Research is required to provide new evidence-based preventive interventions 
and to understand the factors that hamper their implementation within health care 
systems and in the community. Successful implementation of cancer prevention 
requires long-term vision, a dedicated research agenda and funding, sustainable 
infrastructure and cooperation between countries and programmes. In order to develop 
world class prevention research in Europe that translates into effective cancer 
prevention guidelines and policies, we report on the creation of Cancer Prevention 
Europe. This international and multidisciplinary consortium of research institutes, 
organisations and networks of excellence with a common mission of reducing cancer 
morbidity and mortality in European populations through prevention, brings together 
different fields of expertise, from laboratory science through to policy research, as 
well as dissemination of the best evidence, the best quality indicators and the best 
practices used. 
 
 
  
3 
 
Keywords 
 
Cancer prevention, translational research, Europe, multidisciplinary, population-level, 
collaborative research, health promotion, knowledge hub 
 
Declarations of interest: none. 
 
Funding Sources 
 
Cancer Prevention Europe has received funding support from: 
 
Cancer Research UK, London, UK; Danish Cancer Society, Copenhagen, Denmark; 
European Institute of Oncology, Milan, Italy; German Cancer Research Centre, 
Heidelberg, Germany; Imperial College London, London, UK; Karolinska Institute, 
Stockholm, Sweden; UK Therapeutic Cancer Prevention Network, University of 
Leicester, Leicester, UK; World Cancer Research Fund International, London, UK; 
Wereld Kanker Onderzoek Fonds, Amsterdam, The Netherlands. 
 
Acknowledgements 
 
The authors thank Morena Sarzo, from the International Agency for Research on 
Cancer (IARC/WHO), for designing and producing figures 1 and 2, Alice Cotelli & 
Jon Shelton, from Cancer Research UK, for designing and producing figure 3 and Drs 
Kevin Shield & Isabelle Soerjomataram for making available the alcohol attributable 
risk estimates used in figure 3.  
 
 
  
4 
 
Background 
 
The cancer burden in the forty countries of Europe is projected to increase from 
around 3.6 million cases and 1.8 million deaths in 2015 to 4.3 million cases and 2.3 
million deaths in 2035 entirely as a result of population aging and growth [1]. This 
represents an overall increase of around 20%, and translates to an additional 716,000 
cases and 474,000 deaths each year (Table 1) [1]. Further increases are also likely to 
come with changing prevalence of exposure to underlying risk factors, especially 
tobacco, alcohol, an unhealthy diet, obesity and sedentary lifestyles. The changes will 
not be spread equally throughout Europe, with variations dependent on the prevalence 
of risk factors, demographic change and the level of development of health services 
screening and therapeutic options, among other parameters. Specific additional 
challenges within Europe will be posed by factors such as the general influx of 
migrants [2] and by country specific factors such as the dramatic scale of alcohol 
consumption in some countries [3].  
 
The increasing number of cancer patients and survivors (all of whom require long-
term care), coupled with the spiralling costs of therapeutic interventions means that 
governments cannot rely on treatment as their only response to the cancer problem 
[4]. It is undeniably important that the latest understanding of the molecular basis of 
cancer translates through to more effective treatment and clinical services will 
undoubtedly need to be strengthened to face the projected increased number of cancer 
patients. However, for health system sustainability these efforts need to be 
complemented by a renewed focus on prevention of cancer and detection of pre-
malignant lesions. The economics of cancer treatment within rapidly ageing 
populations do not make for cost effective cancer control policies unless aligned to 
public health orientated strategies for evidence-based cancer prevention. The 
considerable physical, social and psychological morbidities associated with most 
cancer treatments also weigh heavily in favour of prevention rather than cure. 
 
Although estimates on the overall preventability of cancer vary [5, 6], there is broad 
agreement that the proportion of cancers that could be prevented on the basis of 
current knowledge would be around 30-40% in westernised countries - if current 
understanding of risk and protective factors was translated into effective primary 
prevention [7-9]. Identification of additional modifiable risk factors would increase 
this prevention potential. Cancer screening and other approaches to early detection of 
pre-malignant lesions can also contribute to reduce cancer incidence and mortality 
while the potential benefits of preventive medicines (for example with aspirin) [10] 
would, if realised, increase the preventive fraction still further. 
 
Cancer prevention strategies are not without challenges in implementation, but the 
potential gains are striking. The dramatic declines in lung and cervical cancer 
incidence and mortality in many European countries following decreases in smoking 
and the implementation of screening, respectively, are evidence of the power of 
successful prevention. In contrast, the absence of decline in these two cancer types in 
other countries can be said to represent failures in the effective implementation of 
prevention.  Figure 1 shows, for example, that the mortality rate for lung cancer 
among UK men, aged 30-79 years, peaked in the early 1970s at a level around 160 
per 100,000 per annum and has since dramatically declined. In contrast, it was not 
until two decades later that the peak mortality rate was reached in Poland and this can 
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partly be attributed to the later commencement of the effective prevention of tobacco 
exposure through national control policy measures. In the UK, the first TV 
advertisement bans and health warnings on cigarette packs appeared in the early 
1960s [14]. Such initial measures were not taken until the late 1980s in Poland [15].  
 
The potential to expand preventive interventions remains large and the evidence base 
for a number of individual level measures has been summarised in the new edition of 
the European Code against Cancer (http://cancer-code-europe.iarc.fr/index.php/en/) 
[16]. Apart from tobacco control, the main pillars for primary cancer prevention are 
usually summarised as interventions to reduce obesity, alcohol consumption, and 
excess sun exposure together with the promotion of physical exercise and a healthy 
diet. Control of environmental and workplace carcinogens and immunisation against 
human papilloma virus (HPV) and hepatitis B virus infections represent other key 
areas for intervention (Figure 2). For all these factors, there is often a lack of clarity 
on or commitment to implement optimum strategies to bring about the required 
changes through behavioural change or policy and regulatory measures.  
 
Although cancer has a number of highly specific risk factors (e.g. HPV infection), 
many are shared with other common diseases notably cardiovascular disease, diabetes 
and chronic respiratory disease. Successful prevention of cancer will, therefore, have 
a significant impact on all of these non-communicable diseases (NCDs) and 
contribute to the UN/WHO “25 by 25” target of a 25% reduction in premature deaths 
from NCDs by 2025 [18]. For example, alcohol consumption is estimated to be an 
attributable factor for over 244,000 cases of cancer in Europe each year (Figures 3a 
and 3b) but interventions to reduce alcohol consumption would also provide 
substantial benefits in terms of reduced morbidity and mortality from, among others, 
cardiovascular disease, liver disease, and accidental injuries [22]. 
 
Cancer is also a disease that has encouraged proliferation of interventions promoted 
for the purposes of prevention that have either been unsupported (or unaddressed) by 
relevant epidemiological (or mechanistic) evidence or for which the magnitude of any 
effect would be insignificant. Many such examples are dietary in origin (e.g. many 
dietary supplements and/or “superfoods”) although others are not (e.g. over-diagnosis 
and over-treatment of small papillary thyroid cancers) [23]. An important component 
of any comprehensive prevention strategy is also to make information available 
regarding interventions that are of no or uncertain benefit.  
 
The scope of cancer prevention  
 
There are multiple, often complementary, targets for cancer prevention. Prevention 
can be undertaken at several levels: from primary to secondary to tertiary prevention. 
 
Primary cancer prevention includes reducing exposure to risk factors, through 
legislation, regulation, education and behavioural change e.g. targeting tobacco 
smoking, alcohol consumption, physical inactivity and obesity alongside avoiding or 
minimising exposure to known carcinogens in the workplace, home and environment 
and vaccinating against oncogenic viruses. Primary prevention involving removal of 
carcinogenic exposures can have the advantage of bringing benefit not just to the 
current generation but also future generations.  
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Primary prevention may also include interventions with preventive medicines (also 
often referred to as chemoprevention) with, for example, selective estrogen receptor 
modulators (tamoxifen, raloxifene) and aromatase inhibitors (exemestane, 
anastrozole) for women at high-risk of breast cancer [24] as well as aspirin and other 
non-steroidal anti-inflammatory drugs (NSAIDs) for colorectal cancer prevention 
[10].  
 
Secondary cancer prevention includes cancer screening, detection of pre-malignant 
lesions and medical prevention to arrest or reverse the carcinogenic process. Effective 
cancer screening is available for cervix, breast and colorectal cancers when 
implemented on a population level and following established European quality 
assurance guidelines [25, 26]. Avoidance of unnecessary treatment and improved 
cost-effectiveness of screening may come through identification of high-risk sub-
groups within the population, including through the use of biomarkers. The use of 
topical diclofenac and other interventions for prevention of skin cancer in patients 
with actinic keratosis could also be considered as secondary prevention [27]. 
 
Tertiary cancer prevention aims to prevent disease recurrence and improve 
prognosis/survival in already diagnosed cancer patients. It can include medical 
prevention but may increasingly focus on exposures previously considered in relation 
to primary prevention (e.g. smoking cessation and increased physical activity).  For 
example, in both breast and colorectal cancer, physical activity decreases the risk of 
developing the disease and higher levels of physical activity are also associated with 
improved survival [28]. 
 
Conceptually, cancer prevention must be considered not only in relation to the natural 
history of the disease but also to the target population to which it is applied i.e. in 
relation to population stratification. Prevention can stretch from the whole 
population through to a few specific individuals, depending on the degree to which 
application of the preventive intervention is stratified. For example, the banning of 
smoking in public places is a primary prevention measure covering the whole 
population whereas control of a carcinogenic occupational chemical may benefit a 
relatively small workforce. Breast cancer screening sees the population stratified to 
include only women within a specified age-range. Other interventions may be based 
on prior biomedical information. For example, aspirin may be used among the 
(relatively) few individuals previously diagnosed with colon polyps or with defined 
genetic conditions such as Lynch syndrome and Familial Adenomatous Polyposis. 
Regular clinical examinations, medical prevention agents and elective surgery may be 
targeted to individuals from families affected by high penetrance genes predisposing 
to cancer, e.g. BRCA1 and BRCA2 [29].  
 
Cancer prevention research 
 
Identifying the causes of different cancers provides the foundation for cancer 
prevention. While much is known, major causes remain undiscovered for many types 
of cancer including several considered relatively common, such as prostate and 
ovarian cancers (Figure 2). Research should also include a consideration of life-course 
exposures including specific windows of vulnerability (e.g. early in life, pregnancy, 
etc). The variation in exposure profiles and cancer patterns across Europe can provide 
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valuable opportunities for trans-national studies of aetiology as demonstrated by the 
30-year old EPIC study [30]. 
Estimating the preventability of cancer requires both assessment of the extent and 
evolution of the cancer burden in different populations (through high quality cancer 
registry information) and information on the prevalence and level of exposure to 
cancer risk (or protective) factors. Surveillance data on such risk factors is required 
within and across different populations, including monitoring changes over time. Both 
for research on causes and for estimation of exposures, it is increasingly important 
that population-based research resources, including those open to biomarker analyses, 
are established and maintained.  The creation of the biobank infrastructure in Europe 
(BBMRI-ERIC) [31] is a good example of recently established shared resources 
which can underpin population-based cancer research. 
 
Where carcinogenic exposures have been identified and quantified (including 
environmental, behavioural and workplace exposures), strategies are required to 
reduce or remove exposures; this implies translating knowledge on causes through to 
interventions which are effective, and implementing these interventions.  
 
Research is also required to evaluate potential new preventive interventions (e.g. new 
policies, screening modalities or agents for medical prevention) and their optimal 
application to, and effect on, individuals or sub-groups within populations. The risks 
of unnecessary treatments, for example over-diagnosis in relation to screening 
programmes, also need to be addressed. For medicines in clinical use repurposed for 
prevention, e.g. aspirin and tamoxifen, there can be a lack of interest from 
pharmaceutical companies in the research required for their re-emergence under the 
umbrella of preventive medicines either because of the cost of long-term safety 
assessment studies or because of the lack of profitability of off-patent drugs.  
 
A common and critical barrier to successful prevention is an inability to translate from 
randomized trials of efficacy to effectiveness in real-life programmes.  It is vital to 
understand the factors which help and hinder the implementation of evidence-based 
preventive interventions within health care systems and in the community. Modern 
methods of communication employing e-learning, multimedia channels and social 
media are needed to support implementation at the individual or population level and 
merit research evaluation as to their effectiveness. Implementation of a preventive 
intervention also requires ongoing monitoring and evaluation and should be an 
integral part of preventive programmes, including continuous assessment of real-life 
cost-effectiveness. In many instances, promoting systems that will allow the 
prevention efforts themselves to have a continuous, evidence-based incremental 
optimization may be the most effective strategy. Such incremental improvements are 
likely to be significantly furthered by the launch of international networks of 
excellence for observing and disseminating the best evidence, the best quality 
indicators and the best practices used.  
 
For all elements of an integrated cancer prevention research programme, effective and 
well-resourced population-based cancer registration systems will be required. This is 
an essential requirement both to define the size and scale of the problem and to 
monitor the impact of interventions. Modern cancer registries will also need to contain 
appropriate identifiers and be fully integrated into national information systems so 
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that data linkages can be formed with both research datasets and routine health and 
other information sources. This will, in turn, require robust solutions to address 
questions of data security and confidentiality and ethical considerations regarding 
patient choice and patient integrity.  
 
Integration of cancer prevention research with translational cancer research 
 
Cancer prevention is entering an exciting period. Advances in basic science are 
beginning to permeate prevention, opening new opportunities. As a consequence, the 
inter-disciplinary nature of cancer prevention is coming to prominence. Advances in 
cancer biology are beginning to underpin progress in cancer registration (through 
changes in molecular classification of tumours) and studies of causes, prevention, 
early detection, diagnosis and treatment. The common soil of molecular science 
promises a bridge from the population to the clinic and is thus fundamental to an 
overall integrated strategy of prevention, early detection and treatment of cancer in 
Europe. This “two-way translational cancer research” [32] provides added value by 
drawing advances in cancer biology into both the clinic and the population settings. 
 
There are many areas where the molecular sciences can inform cancer prevention. 
Examples include mutation spectra in tumours providing fresh hypotheses about risk 
factors, patterns of gene expression or metabolite profiles being used to characterise 
environmental exposures and genetic markers allowing causes of cancer to be 
identified within susceptible sub-groups of the population [7, 33].  One of the most 
interesting possibilities is whether the over-treatment associated with some cancer 
screening procedures may be circumvented by biomarkers, indicating pre-cancerous 
lesions with higher or lower propensity to progress to malignancy [34]. This is both a 
scientific and a policy issue with dramatic implications for the health of Europeans 
and for healthcare expenditure. A typical example is prostate cancer and the 
development of new biomarkers to avoid the current problems of over-treatment 
following a positive prostate specific antigen test. Unfortunately, unlike 
cardiovascular disease (e.g. cholesterol levels) or diabetes (e.g. hyperglycemia), well-
validated, non-invasive cancer biomarkers which indicate early stage disease 
requiring treatment are currently lacking. This is proving to be a significant barrier to 
progress in prevention research. Validation of surrogate biomarkers can render these 
as powerful research tools, e.g. as with using mammographic density reduction as a 
marker of tamoxifen effect [35] but there are relatively few equivalent examples. 
 
While emphasizing the fresh opportunities that may come from cancer biology, it 
must be stressed that the inter-disciplinary nature of cancer prevention stretches not 
only down into the sub-microscopic but up into the supra-macroscopic by addressing 
the “causes of the causes”. This involves socio-economic and environmental factors 
such as poverty, lack of education, the built environment, climate and transport [36]. 
It is vital that the public health orientation of cancer prevention is not lost by focusing 
on ever smaller target populations in what has been termed “precision prevention” 
[37]. Equally, just as cancer risk factors impact on different sectors of the community 
to differing extents depending on income, education, race and gender, so do 
prevention policies and their implementation.  A strong emphasis must be placed on 
addressing the challenges of policy across sectors at sub-national, national and 
international levels.  
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The community for cancer prevention 
Institutional infrastructure for disease prevention tends to be fragmented at all levels 
(local, national and international). There are very few exemplars of “prevention 
centres” analogous to primary, secondary or tertiary care centres. Likewise there are 
few centres of research excellence in prevention unlike the many world class cancer 
treatment centres in Europe (as in the Comprehensive Cancer Centres or their 
equivalents seen in most European countries). International collaborative consortia 
(e.g. the European Organisation for Research and Treatment of Cancer - EORTC) are 
the norm in the employment of clinical trials in development of new treatments. The 
absence of such consortia in the field of prevention inhibits the development of world 
class prevention research.  
 
Prevention is also different from treatment in terms of organisational responsibility, 
public perception and culture. Within any jurisdiction, it is usually relatively clear 
who has political responsibility for health care (Government Ministry of Health or 
equivalent), who should undertake it (health professionals), where it should be carried 
out (hospitals, primary care centres) and how to assess outcomes (do sick people get 
better?). While this is an over- simplification, all of these parameters are considerably 
more complicated for prevention. This, in turn, complicates research structurally (who 
is responsible for ensuring that high-quality prevention research is carried out?) and 
methodologically (it needs to be population-based, with long time lags before 
outcomes become evident).  
 
Cancer prevention research and assembly of the evidence-base to underpin preventive 
interventions depends on experts from many disciplines and domains including 
epidemiology, public health, cancer registries, clinical science, general practice, 
health services, health psychology, economics, social sciences, statistics, 
implementation science, high-technology education and e-learning, as well as the 
basic and applied laboratory sciences. Many of these disciplines are to be found, for 
example, in institutes of public health, universities and government departments in 
addition to those within the cancer treatment and care settings. Certainly the 
approaches and disciplines needed for cancer prevention require broad communities 
of healthcare and research professionals to be assembled. 
 
Successful coordination of cancer prevention requires long-term vision, a dedicated 
research agenda and funding for such research. It also requires a sustainable 
infrastructure and cooperation between countries and programmes to fill gaps in the 
evidence-base for prevention, to avoid common pitfalls in implementation and to 
share capacity for research training and quality improvement. 
 
The political context for cancer prevention  
 
Since the UN General Assembly high-level meeting on NCDs in New York in 2011 
[18], governments have become sensitized to the importance of cancer, cardiovascular 
disease, diabetes and chronic respiratory diseases as a major burden on health and 
economic development in the coming decades. The emphasis has been on shared risk 
factors and preventive interventions or treatments to achieve the “25 by 25” target 
[18].  
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The World Health Organization-led global response to the challenge of NCDs, 
including cancer, entails a strong emphasis on population-level prevention and low 
cost treatment of early stage disease (e.g. anti-hypertensive drugs, HPV vaccination, 
cervical cancer screening, etc.) [38]. In contrast, a majority of recent investment in 
combating cancer, including in Europe, has been dedicated to developing highly 
specialised, tailored approaches to new treatments based on the molecular genetics of 
an individual tumour (precision medicine), requiring referral to specialist tertiary 
centres. This partly reflects the exciting opportunities consequent to advances in 
cancer biology but also the greater financial incentives linked to development of new 
chemotherapeutic agents.       
 
This apparent dichotomy between the cancer control approaches identified and 
promoted by government in the context of the NCD agenda and those currently 
prioritised in practice drives the simple concept of bringing these together in a “twin-
track” approach (prevention and treatment) to enable effective cancer control in 
Europe. This approach is required if national governments are to achieve sustainable 
health care in the 21st century. In broadening the agenda for cancer control in this 
way, it becomes evident that success will only come through a cross-sectorial 
approach, stretching beyond health to encompass areas such as social inequalities, 
environment, transport, workplace etc. Health must be embedded in all policies.  
 
The Member States of the World Health Organization at the World Health Assembly 
2017 acknowledged the particular challenges and approaches in relation to cancer 
compared to other NCDs by adoption of a landmark resolution on cancer prevention 
and control [39]. The resolution noted that “risk reduction has the potential to prevent 
around half of all cancers” and emphasized the importance of implementing primary 
prevention and early detection in addition to evaluation and follow-up using 
population-based cancer registries. The resolution also urged countries “to promote 
cancer research to improve the evidence base for cancer prevention and control, 
including research on health outcomes, quality of life and cost-effectiveness”. 
 
The science of cancer prevention offers an opportunity to draw together a number of 
relevant activities at the level of the European Commission (EC), where important 
investments are already being made and added value can be envisaged. For example, 
there are a number of investments in large collaborative research studies e.g. on the 
exposome (e.g. HELIX in exposomics [40]) and other areas of environment, nutrition 
and health of direct relevance to cancer prevention. Equally there are important 
investments in research infrastructure, such as biobanks (e.g. the European 
infrastructure BBMRI-ERIC [31], the developing countries biobanking network 
BCNet [41] and the international biobanking society ISBER [42] etc.) and large 
population-based cohort studies of chronic diseases (e.g. BBMRI-LPC [43]), which 
provide platforms for research on cancer prevention. There is a major opportunity to 
bring cancer prevention into the future research agenda within DG Research and 
Innovation to meet the needs of Member States in relation to cancer control, in liaison 
with DG Health and the EC Steering Group on Health Promotion, Disease Prevention 
and Management of Non Communicable Diseases. 
 
A new structure for cancer prevention research in Europe 
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To deal with these multiple challenges and opportunities facing cancer prevention 
research in Europe we propose the creation of a consortium of organisations focused 
on prevention, tentatively entitled: Cancer Prevention Europe (CPE) with a mission to 
reduce morbidity and mortality from cancer in European populations through 
prevention and earlier diagnosis of the disease. This will be accomplished through 
research into how the evidence base for optimal implementation of known preventive 
strategies can be extended, by dissemination of established best practices in 
prevention, by facilitating the translation of innovative research into effective cancer 
prevention guidelines and policies, and by furthering research into the identification 
of novel preventive strategies and targets. 
 
CPE will be broad in scope covering a spectrum of research from behavioural science 
and policy research through to development of novel medical preventive agents. 
Assessment of the cost-effectiveness of different interventions, in relation to costs of 
treatment, care and productivity loss will be a core component of the initiative. 
Primary, secondary and tertiary prevention will be encompassed and emphasis will 
also be placed on the research evaluation and advocacy dimensions of the prevention 
agenda. 
 
The CPE ambition is to transform the current landscape through the creation of a 
multidisciplinary consortium of research institutes and organisations within Europe 
dedicated to cancer prevention.  It would seek to facilitate innovative world class 
research capable of translation into effective cancer prevention guidelines and policies 
at national and international level. CPE will offer an integrated infrastructure capable 
of assuring high quality research and each CPE partner institution will bring specific 
fields of expertise in cancer prevention research as well as in dissemination and 
informing policy and practice. 
 
The agenda for CPE would include (1) research into optimising the implementation of 
known preventive strategies, (2) dissemination and research translation to inform 
policy and practice and (3) the identification of novel targets for prevention. Specific 
research activities for CPE could include the following areas: cancer registration; 
cancer aetiology (including recurrence); development and evaluation of preventive 
interventions (primary, secondary, tertiary); health economics and implementation 
research to enhance the effectiveness of intervention programmes. These would be 
supported by a range of platforms, networks and infrastructures and draw together a 
wide network of partners. Training and capacity building would be integral to the 
initiative.  
 
The conduct of prevention research and the collation of information on cancer 
prevention would be translated through to an evidence-base on which cancer control 
policy could be based. 
 
Inherent to the philosophy of CPE would be the sharing of resources (including 
existing research platforms, such as cancer registries, screening registries, clinical 
databases and biospecimen repositories etc), the sharing of data (establishing 
multicentre, trans-national research projects to provide sufficient statistical power to 
identify modest-size effects and making use of multidisciplinary approaches); and by 
the creation of a central repository in Europe of information pertinent to cancer 
prevention (a European Knowledge Hub on Cancer Prevention). Suitable and 
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acceptable legal frameworks would be established within CPE to permit information 
exchange, to monitor regulations and to highlight potential and actual barriers to 
progress through any implemented legislation. 
 
There are a number of large prospective cohort studies in Europe, both in adults and 
children/adolescents, which permit the study of the causes of cancer and other NCDs 
throughout the life-course. Often the maintenance of these research platforms 
nationally is difficult and failure to identify long-term support jeopardizes the 
potential benefits. A good example is the 30 or so cohorts which were a part of the 
EC-financed BBMRI-LPC [43], including a total of around 2 million participants and 
comprising large datasets on exposures, clinical outcomes as well as associated 
biobanks, the latter of which in turn cooperate through the EU-funded infrastructure 
BBMRI-ERIC [31].  
 
Both population cohort data and biospecimens offer major research platforms for 
understanding the causes and prevention of cancer. There are other studies of different 
design e.g. multi-centre case-control studies, randomized clinical or community-based 
trials, and the evaluation of natural experiments within or between countries which 
offer additional opportunities for prevention research. Bringing together such 
platforms and new initiatives under a co-ordinated prevention agenda would bring 
major added-value to future and past EC research investment; in contrast, to abandon 
these now would result in a failure to realize the benefits of prior investments. 
 
The development of an alliance of organizations focused on cancer prevention would 
provide a focal point for reflection on professional training and career development 
within the context of a network of leading institutions, resulting in fellowships, 
courses, PhD programmes etc. This would be particularly valuable in the area of 
cancer prevention which involves different disciplines and where no simple career 
pathway is evident. 
 
The proposed CPE Knowledge Hub would provide policy-makers access to data on 
cancer burden, risk factor prevalence, attributable fraction of cancers associated with 
known risk factors and effective preventive interventions. The evidence-base would 
not stop at identifying risk factors or potential interventions but would evaluate the 
effectiveness of preventive interventions supported by legislation, regulation and 
other policy initiatives in the context of broader assessments. 
 
This exercise should not duplicate existing efforts in collating data from these 
different domains but, where possible, would draw upon existing resources and work 
in cooperation, providing links, where applicable, to existing sources of information. 
In parallel, recognized leadership in cancer prevention in Europe would serve as a 
reliable resource both for collating but also interpreting the scientific evidence-base 
for prevention and making this available to the EU and national policymakers. 
International cooperation would provide such evidence in an independent, 
autonomous manner.  
 
The outlook of CPE would be designed to complement parallel initiatives on 
treatment, such as the recently established Cancer Core Europe [44]. Indeed there are 
many areas of overlap in relation to methodology (e.g. laboratory, epidemiology, 
biostatistics and bioinformatics), platforms (e.g. equipment, biobanks and database 
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linkage) and opportunities to build on the understanding of underlying mechanisms of 
carcinogenesis for translational research both to the clinic and population settings. 
There are many potential benefits in having a “twin-track” approach to research into 
prevention and treatment, jointly planned and developed in order to provide a truly 
comprehensive approach to cancer control. Notwithstanding, prevention research has 
been consistently under-resourced such that public funding needs to be increased and 
focused in this area. 
 
 
Creation of Cancer Prevention Europe 
 
CPE has initially been established as a core group of eight “Member” institutes 
[Cancer Research UK, London, UK; Danish Cancer Society, Copenhagen, Denmark; 
European Institute of Oncology, Milan, Italy; German Cancer Research Centre, 
Heidelberg, Germany; Imperial College London, London, UK; Karolinska Institute, 
Stockholm, Sweden; UK Therapeutic Cancer Prevention Network, Leicester, UK; 
World Cancer Research Fund International, London, UK/Wereld Kanker Onderzoek 
Fonds, Amsterdam, The Netherlands],  each committed to make an annual financial 
contribution within a formal Consortium Agreement together with a secretariat hosted 
by the International Agency for Research on Cancer, Lyon, France. The consortium 
funding will be used to appoint a senior Co-ordinating Scientific Officer with 
administrative support and an operating budget. This commitment will allow a focal 
point to co-ordinate development of the CPE priority actions within a 5-year Strategic 
Plan, including definition of the possible instruments to provide sustainability, the key 
partnerships and relevant stakeholders. The CPE Consortium also includes the Maria 
Sklodowska-Curie Institute - Oncology Centre, Warsaw, Poland as an Associate 
Member. 
 
CPE will undertake the following actions to give shape and direction to the alliance in 
the first phase and to contribute to delivery of the proposed Strategic Plan: 
 
1. Propose an agenda for future cancer prevention research activity at a European 
level through advocacy within relevant EU bodies, EU member states, non-EU 
European countries, professional organisations, cancer and public health 
institutes, research sponsors, charities and patient groups. 
 
2. Provide overviews and guidance on the “state of the art” regarding cancer 
prevention, on research currently in progress within Europe and on research 
priorities for the future. 
 
3. Develop and define pan-European high-quality research projects involving the 
participation of CPE and other partners and where added value is provided 
through international, multicentre collaboration. 
 
4. Positively influence investment in cancer prevention research from the EU, 
governmental bodies and NGOs. 
 
5. Establish a European Knowledge Hub on Cancer Prevention to promote rapid 
dissemination of best practice in cancer prevention, expansion of evidence 
14 
 
evaluation activities and definition of unanswered questions requiring research 
investment. 
 
 
Other European Institutes or organisations who are committed to collaborative 
research in cancer prevention and are interested in becoming affiliated with CPE are 
invited to contact the Secretariat at cpe@iarc.fr. 
Conclusion 
 
An international consortium to launch, evaluate and incrementally improve evidence-
based prevention strategies within Europe will further the prospects for ensuring 
populations have access to and benefit from the effective cancer prevention to which 
they are entitled. 
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TABLES AND FIGURES 
 
Table 1 
 
Estimated number (millions) of new cases and deaths and percent increase for all 
cancers (excluding non-melanoma skin cancer) for 2015 and 2035 by sex in 
Europe. 
 
 2015 2035 
 New cases Deaths New cases  
(% increase) 
Deaths  
(% increase) 
Males 1.9 1.0 2.4 (26%) 1.3 (30%) 
Females 1.7 0.8 1.9 (12%) 1.0 (25%) 
All 3.6 1.8 4.3 (19%) 2.3 (28%) 
 
Source: [1] 
 
  
20 
 
Figure 1. Male lung cancer mortality rates in the UK (1950-2013) and Poland 
(1960-2013) and selected tobacco control interventions in the two countries. 
 
 
 
Sources: Mortality data [11]; Smoking prevalence in the UK [12]; Smoking 
prevalence Poland [13]; Interventions [14, 15]  
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Figure 2. Most common cancers in Europe: estimated incidence for 2012 and 
proportion potentially preventable from changes in currently established risk 
and protective factors. 
 
 
 
Sources: Incidence data [1]; Risk factor attributable fractions [17] 
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Figure 3a. Cancer caused by alcohol in Europe: proportions of all cancers and 
number of cancers that could be prevented by alcohol control. 
 
The 7.1% of all cancer cases in Europe attributable to alcohol consist predominantly 
of cancers of the breast, colorectum and lip, oral cavity, oropharynx and hypopharynx, 
but also cancers of the oesophagus, larynx and liver. 
 
 
 
Sources: Incidence data [1]; Adult per capita consumption of alcohol for 2000 [19]; 
Risk estimates [20]; Methodology [21] 
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Figure 3b. Cancer caused by alcohol in Europe: country summaries 
 
The charts below show, for each country in Europe, the percentage of all cancers 
attributable to alcohol consumption (the population attributable fraction or PAF) and, 
adjacent to each country name, the number of new cases this represents each year. 
 
 
 
Sources: Incidence data [1]; Adult per capita consumption of alcohol for 2000 [19]; 
Risk estimates [20]; Methodology [21] 
 
 
